- Home
- CYH vs ATAI Comparison
CYH vs ATAI Comparison
Compare CYH & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- ATAI
- Stock Information
- Founded
- CYH 1985
- ATAI 2018
- Country
- CYH United States
- ATAI Germany
- Employees
- CYH N/A
- ATAI N/A
- Industry
- CYH Hospital/Nursing Management
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- CYH Health Care
- ATAI Health Care
- Exchange
- CYH Nasdaq
- ATAI Nasdaq
- Market Cap
- CYH 410.5M
- ATAI 444.7M
- IPO Year
- CYH 1991
- ATAI 2021
- Fundamental
- Price
- CYH $3.08
- ATAI $4.72
- Analyst Decision
- CYH Hold
- ATAI Strong Buy
- Analyst Count
- CYH 8
- ATAI 3
- Target Price
- CYH $3.57
- ATAI $13.33
- AVG Volume (30 Days)
- CYH 1.5M
- ATAI 4.8M
- Earning Date
- CYH 10-22-2025
- ATAI 11-12-2025
- Dividend Yield
- CYH N/A
- ATAI N/A
- EPS Growth
- CYH N/A
- ATAI N/A
- EPS
- CYH N/A
- ATAI N/A
- Revenue
- CYH $12,647,000,000.00
- ATAI $2,309,000.00
- Revenue This Year
- CYH N/A
- ATAI $712.99
- Revenue Next Year
- CYH $2.46
- ATAI N/A
- P/E Ratio
- CYH N/A
- ATAI N/A
- Revenue Growth
- CYH 0.81
- ATAI 510.85
- 52 Week Low
- CYH $2.24
- ATAI $1.03
- 52 Week High
- CYH $6.29
- ATAI $5.34
- Technical
- Relative Strength Index (RSI)
- CYH 62.03
- ATAI 61.12
- Support Level
- CYH $2.87
- ATAI $4.50
- Resistance Level
- CYH $3.13
- ATAI $4.75
- Average True Range (ATR)
- CYH 0.13
- ATAI 0.28
- MACD
- CYH 0.03
- ATAI -0.04
- Stochastic Oscillator
- CYH 88.64
- ATAI 59.28
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.